α-synuclein: Between synaptic function and dysfunction

Histology and Histopathology

Volumn 18, Issue 4, 2003, Pages 1257-1266

  Di Rosa, G ^a,b   Puzzo, D ^a,b   Sant'Angelo, A ^a,b   Trinchese, F ^a,b   Arancio, Ottavio ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Neurotransmission; Parkinson disease; Plasticity; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; ANTISENSE OLIGONUCLEOTIDE; NITRIC OXIDE;

AUTOSOMAL DOMINANT DISORDER; DEMENTIA; ENVIRONMENTAL FACTOR; GENE; GENE MUTATION; HUMAN; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN DEFECT; REVIEW; SYNAPSE; SYNUCLEINOPATHY;

ALPHA-SYNUCLEIN; ANIMALS; ENVIRONMENT; HUMANS; MUTATION; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SYNAPSES; SYNAPTIC TRANSMISSION; SYNUCLEINS; UBIQUINONE; UBIQUITIN-PROTEIN LIGASES;

VERTEBRATA;

EID: 0142063037     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Abeliovich A., Schmidt Y., Farinas I., Choi-Lundberg D., Ho W.-H., Castillo P.E., Shinsky N., Garcia Verdugo J.M., Armanini M., Ryan A., Hynes M., Philips H., Sulzer D., Rosenthal A. (2000). Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Arawaka S., Saito Y., Muruyama S. and Mori H. (1998). Lewy bodies in neurodegeneration with brain iron accumulation type 1 is immunoreactive for α-synuclein. Neurology 51, 881-889.
3. Arima K., Ueda K., Sunohara N., Hirai S., Izumiyama Y., Tonozuka-Uehara H. and Kawai M. (1998). Immunoelectron-microscopic demonstration of NACPα-Synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 808, 93-100.
4. Augustine G.J., Burns M.E., De Bello W.M., Pettit D.L. and Schweizer F.E. (1996). Exocytosis: Proteins and perturbations. Ann. Rev. Pharmacol. Toxicol. 36, 659-701.
5. Baba M., Nakajo S., Tu PH., Tomita T., Nakaya K., Lee VM.Y., Trojanowski J.Q. and Iwatsubo T. (1998). Aggregation of a - Synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879-884.
6. Brady S.T. (1985). In: Neuromethods. Boulton A.A. and Baker G.B. (eds). Humana Press. Clifton Park N.J. (ed). Vol. 1. pp. 419-459.
7. Bayer T.A., Jakala P., Hartmann T., Egensperger R., Buslei R., Falkai P. and Beyreuther K. (1999). Neural expression profile of alpha-synuclein in developing human cortex. Neuroreport 10, 2799-2803.
8. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., McIlwain K.L., Orrison B., Chen A., Ellis C.E., Paylor R., Lu B. and Nussbaum R.L. (2002). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22, 8797-8807.
9. Castillo P.E., Malenka R.C. and Nicoll R.A. (1997). Kainate receptors mediate a slow postsynaptic current in hippocampal CA3 neurons. Nature 388, 182-186.
10. Clayton D.F. and George J.M. (1998). The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249-254.
11. Clayton D.F. and George J.M. (1999). Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129.
12. Coyle J.T. (1997). Biochemical aspects of the neurotransmission in the developing brain. Int. Rev. Neurobiol. 20, 65-102.
13. Culvenor J.G., McLean C.A., Cutt S., Campbell B.C.V., Maher F., Jakalà P., Hartmann T., Beyreuther K., Masters C.L. and Li Q.X. (1999). Non-Ab component of Alzheimer's disease amyloid (NAC) revisited: NAC and α-synuclein are not associated with Ab amyloid. Am. J. Pathol. 155, 1173-1181.
14. Davidson W.S., Jonas A., Clayton D.F. and George J.M. (1998). Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
15. Dickson D.W. (2000). Alzheimer-Parkinson disease overlap: Neuropathology. In: Neurodegenerative Dementias: Clinical Features and Pathological Mechanisms. Clark C.M. and Trojanowski J.Q. (eds). McGraw-Hill. New York. pp 247-259.
16. Dittman J.S. and Regehr W.G. (1998). Calcium dependence and recovery kinetics of presynaptic depression at the climbing fiber to Purkinje cell synapse. J. Neurosci. 18, 6147-6162.
17. Duda J.E., Shah U., Arnold S.E., Lee V.M. and Trojanowski J.Q. (1999). The expression of α-, β- and γ-synucleins in olfactory mucosa from patients with and without neurodegenerative disease. Exp. Neurol. 160, 515-522.
18. Duda J.E., Giasson B.I., Chen Q., Gurt L., Hurtig H.I., Stern M.B., Gollomp S.M., Ischiropoulos H., Lee V.M. and Trojanowski J.Q. (2000). Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 57, 1439-1445.
19. Dunnet S.B. and Bjorklund A. (1999). Prospects for new restorative and neuroprotective treatment in Parkinson's disease. Nature 399, A32-A39.
20. El-Agnaf O.M.A., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neill D. and Wallace A. (1998). Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS Lett. 440, 71-75.
21. Epand R.M. (1993). The Amphipathic Helix. CRC Press, Boca Raton. FL.
22. Frohman M.A. and Morris A.J. (1996). Rho is only ARF the story. Phospholipid signaling. Curr. Biol. 6, 945-947.
23. Galvin J.E., Lee V.M., Schmidt M.L., Tu P.H., Iwatsubo T., Trojanowski J.Q. (1999). Pathobiology of the Lewy body. Adv. Neurol. 80, 313-324.
24. Galvin J.E., Lee V.M.Y. and Trojanowski J.Q. (2001). Synucleinopathies: Clinical and pathological implications. Arch. Neurol. 58, 186-190.
25. Garris P.A., Kilpatrick M., Bunin M.A., Michael D., Walker Q.D. and Wightman R.M. (1999). Dissociation of dopamine release in the nucleus accumbens from intracranial self stimulation. Nature 398, 67-69.
26. George J.M., Jim H., Woods W.S. and Clayton D.F. (1995). Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372.
27. Giasson B.I., Uryu K., Troianowski J.Q. and Lee V.M.Y. (1999). Mutant and wild type human a -synuclein assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619-7622.
28. Giasson B.I., Duda J.E., Murray I.V.J., Chen Q., Souza J.M., Hurtig H.I., Ischioropoulos H., Trojanowski J.Q. and Lee V.M.Y. (2000). Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
29. Giasson B.I., Galvin J.E., Lee V.M.Y. and Troianowski J.Q. (2000). The cellular and molecular pathology of Parkinson's disease. In: Neurodegenerative Dementias: Clinical Feature and Pathological Mechanisms. Clark C.M. and Trojanowski J.Q. (eds) Mc Graw-Hill Co. New York. pp 219-228.
30. Giasson B.I., Ischiropoulos H., Lee V.M.Y. and Troianowski J.Q. (2002). The relationship between oxidative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radical Biol. Med. 32, 1264-1275.
31. Goda Y. and Sudhof T.C. (1997). Calcium regulation of neurotransmitter release: Reliability unreliable? Curr. Opin. Cell. Biol. 9, 513-518.
32. Goedert M. (1997). Familial Parkinson's disease. The awakening of alpha-synuclein. Nature 388, 232-233.
33. Goedert M. (1999). Filamentous nerve cell inclusions in neurodegenerative diseases: Tauopathies and alpha-synucleiopathies. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 354, 1101-1118.
34. Gomis A., Burrone J. and Lagnado L. (1999). Two actions of calcium regulate the supply of releasable vesicles at the ribbon synapse of retinal bipolar cells. J. Neurosci. 19, 6309-6317.
35. Good P.F., Hsu A. Werner D.P., Perl C. and Olanow C.W. (1998). Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-342.
36. Grace A.A. and Bunney B.S. (1984). The control of firing pattern in nigral dopamine neurons: Burst firing. J. Neurosci. 4, 2877-2890.
37. Hashimoto M. and Masliah E. (1999). Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol. 9, 707-720.
38. Hattori N., Shimura H., Kubo S., Wang M., Shimizu N., Tanaka K. and Mizuno M. (2000). Autosomal recessive juvenile parkinsonism: A key to understanding nigral denervation in sporadic Parkinson's disease. J. Neural Transm. Suppl. 60, 101-116.
39. Hirokawa N. (1998). Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279, 519-526.
40. Horger B.A., Nishimura M.C., Armanini M.P., Wang L.C., Poulsen K.T., Rosenblad C., Kirik D., Moffat H., Simmons L., Johnson E. Jr., Milbrandt J., Rosenthal A., Bjorklund A., Vandlen R.A., Haynes M.A. and Philips H.S. (1998). Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18, 4929-4937.
41. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M. and Arnold S.E. (2000). Alpha- synuclein cortical Lewy bodies are markers for dementia. Neurology 54, 1916-1921.
42. Hsu L.J., Mallory M., Xia Y., Veinbergs I., Hashimoto M., Yoshimoto M., Thal L.J., Saitoh T. and Masliah E. (1998). Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J. Neurochem. 71, 338-344.
43. Irizarry M.C., Kim T.W., McNamara M., Tanzi R.E., George J.M., Clayton D.F., and Hyman B.T. (1996). Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889-895.
44. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., Rohan De Silva H.A., Kittel A. and Saitoh T. (1995). The precursor protein of non-Aß component of Alzheimer disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
45. Jakes R., Spillantini M.G. and Goedert M. (1994). Identification of two distinct synucleins from human brain. FEBS Lett. 345, 27-32.
46. Jenco J.M., Rawlingson A., Daniels B. and Morris A.J. (1998). Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by alpha-and beta-synucleins. J. Biol. Chem. 273, 26292-26294.
47. Jensen P.H., Nielsen M.S., Jakes R., Dotti C.G. and Goedert M. (1998). Binding of α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 26292-26294.
48. Jensen P.H., Hager H., Nielsen M.S., Hoijrup P., Gliemann J. and Jakes R. (1999). α-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorilation of serine residues 262 and 356. J. Biol. Chem. 274, 25481-25489.
49. Jin H. and Clayton D.F. (1997). Localized changes in immediate-early gene regulation during sensory and motor learning in zebra finches. Neuron 19, 1049-1059.
50. Jo E., McLaurin J., Yip C.M., George-Hyslop P. and Fraser P.E. (2000). α-Synuclein membrane interactions and lipid specifity. J. Biol. Chem. 275, 34328-34334.
51. Junn E. and Mouradian M.M. (2002). Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320, 146-150.
52. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzierlorz A., Okochi M., Leimer U., Van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A. and Haass C. (2000). Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373.
53. Kakizuka A. (1998). Protein precipitation - A common etiology in neurodegenerative disorders. Trend Genet. Sci. 14, 396-402.
54. Kennedy R.T., Jones S.R. and Wightman R.M. (1992). Dynamic observation of dopamine autoreceptor effects in rat striatal slices. J. Neurochem. 59, 449-455.
55. Khodilov N.G., Neysat M., Oo T.F., Lo S.E., Larsen K.E., Sulzer D. and Burke R.E. (1999). Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J. Neurochem. 73, 2586-2599.
56. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998). Mutations in the parking gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
57. Kitada T., Asokawa S., Matsumine H., Hattori N., Shimura H., Minoshima S., Shimizu N. and Mizuno Y. (2000). Progress in the clinical and molecular genetics of familial parkinsonism. Neurogenetics 2, 207-218.
58. Kruger R., Kuhn W., Muller T., Woitalia D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L. and Riess O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nature Genet. [letter]. 18, 106-108.
59. Lippa C.F., Fujiwara H., Mann D.M.A., Giasson B., Baba M., Schmidt M.L., Nee L.E., O'Connel B., Pollen D.A., St. George-Hyslop P., Ghetti B., Nochlin D., Bird T.D., Cairns N.J., Lee V.M.Y., Iwatsubo T. and Trojanowski J.Q. (1998). Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365-1370.
60. Lippa C.F., Schmidt M.L., Lee V.M.Y., Iwatsubo T. and Troianowski J.Q. (1999). Antibodies to α-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol. 45, 353-357.
61. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y. and Brice A. (2000). Association between early-onset Parkinson's disease and mutations in the parking gene. French Parkinson's disease genetics study group. N. England J. Med. 342, 1560-1587.
62. Maroteaux L. and Sheller R.H. (1991). The rat brain synucleins; Family of proteins transiently associated with neuronal membrane. Mol. Brain Res. 11, 335-343.
63. Maroteaux L., Campanelli J.T. and Sheller R.H. (1988). Synuclein: A Neuron-specific protein localized to the nucleus and Presynaptic Nerve Terminal. J.- Neurosci. 8, 2804-2815.
64. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A. and Mucke L. (2000). Dopaminergic loss and inclusion body formation in a -synuclein mice: Implications for neurodegerative disorders. Science 287, 1265-1269.
65. Mizuno Y., Hattori N., Kitada T., Matsumine H., Mori H., Shimura H., Kubo S., Kobayashi H., Asakawa S., Minoshima S. and Shimizu N. (2001). Familial Parkinson's disease- Alpha-synuclein and parking. Adv. Neurol. 86, 13-21.
66. Mochizuki H., Goto K., Mori H. and Mizuno Y. (1996). Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137, 120-123.
67. Murphy D.D., Rueter S.M., Trojanowski J.Q. and Lee V.M.Y. (2000). Synucleins are developmentally expressed and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
68. Nakajo S., Tsukada K., Omata K., Nakamura Y. and Nakaya K. (1993). A new brain-specific 14-kDa protein is a phosphoprotein. Its complete amino acid sequence and evidence for phosphorylation. Eur. J. Biochem. 217, 1057-1063.
69. O'Donnell V.B., Eiserich J.P., Bloodsworth A., Chumley P.H., Kirk M., Barnes S., Darley-Usmar V.M. and Freeman B.A. (1999). Nitration of unsaturated fatty acids by nitric oxide-derived reactive species. Chem. Res. Toxicol. 301, 454-470.
70. Osterova N., Petruccelli L., Farrer M., Mehta N., Choi P., Hardy J. and Wolozin B. (1999). Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791.
71. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M. and Ischiropoulos H. (2001). Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21, 8053-8061.
72. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehijia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L. and Nussbaum R. (1997). Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
73. Rathke-Hartlieb S., Kahle P.J., Neumann M., Ozmenn L., Haid S., Okochi M. and Schulz J.B. (2001). Sensitivity to MPTP is not increased in Parkinson's disease-associate mutant alpha-synuclein transgenic mice. J. Neurochem. 77, 1181-1184.
74. Rebec G.V. (1997). Dopamine, glutamate, and behavioral correlates of striatal neuronal activity. Adv. Pharmacol. 42, 734-740.
75. Schlossmacher M.G., Frosch M.P., Gai W.P., Medina M., Sharme N., Forno L., Ochiishi T., Shimura H., Sharon R., Hattori N., Langston J.W., Mizuno Y., Hyman B.T., Selkoe D.J. and Kosik K.S. (2002). Parking localizes to the Lewy bodies of Parkinson's disease and dementia with Lewy body. Am. J. Pathol. 160, 1655-1667.
76. Schluter O.M., Schnell E., Verhage M., Tzonopoulos T., Nicoll R.A., Janz R., Malenka R.C., Geppert M. and Sudhof T.C. (1999). Rabphili knock-out mice reveal that rabphilin is not required for rab3 function in regulating neurotransmitter release. J. Neurosci. 19, 5834-5846.
77. Seiden L.S., Sabol K.E. and Ricaurte G.A. (1993). Amphetamine: Effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33, 639-677.
78. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K. and Suzuki T. (2000). Familial Parkinson's disease gene product, parking, is a ubiquitin-protein ligase. Nat. Genetic. 25, 302-305.
79. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S. and Selkoe D.J. (2001). Ubiquitination of a new form of a -synuclein by parking from human brain: Implications for Parkinson's disease. Science 293, 263-269.
80. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q., Jakes R. and Goedert M. (1997). α-Synuclein in Lewy bodies. Nature 388, 839-840.
81. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L. and Goedert M. (1998). Filamentous a -Synuclein inclusions link multiple system atrophy with Parkinson's Disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205-208.
82. Stamoudis C.X., Comery T.A., Armstrong K.E., George J.M., Clayton D.F. and Greenough W.T. (1996). Modulation of visual cortex synelfin immuno-reactivity in rats reared in a complex environment. Soc. Neurosci. Abstr. 22, 736.
83. Stevens C.F. and Wesseling J.F. (1998). Activity-dependent modulation of the rat at which synaptic vesicles become available to undergo exocytosis. Neuron 21, 415-424.
84. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T., Tsuji S. and Ikuta F. (1994). Familial juvenile parkinsonism: Clinical and pathologic study in a family. Neurology 44, 437-441.
85. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L. and Masliah E. (1998a). Abnormal accumulation of NACP/a-Synuclein in neurodegenerative disorders. Am. J. Pathol. 152, 367-372.
86. Takeda A., Hashimoto M., Mallory M., Sundsumo M., Hansen L., Sisk A. and Masliah E. (1998b). Abnormal distribution of the non-Ab component of Alzheimer's disease amyloid precursora-Synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab. Invest. 78, 1169-1177.
87. Tanaka K., Suzuki T., Chiba T., Shimura H., Hattori N. and Mizuno Y. (2001). Parking is linked to the ubiquitin pathway. J. Mol. Med. 79, 482-494.
88. Tompkins M.M., Basgall E.J., Zampini E. and Hill W.D. (1997). Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am. J. Pathol. 150, 119-131.
89. Trojanowsi J.Q., Goedert M., Iwatsubo T. and Lee V.M.Y. (1999). Fatal attractions-abnormal protein aggregation and neuron death in Parkinsons-disease and Lewy body dementia. Cell Death Diff. 5, 832-837.
90. Tu P., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q. and Lee V.M. (1998). Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol. 44, 415-422.
91. Ueda K., Fukushima H., Masliah E., Xia Y., Yoshimoto M., Otero D., Kondo J., Ihara Y. and Saitoh T. (1993). Molecular cloning of cDNA encoding an recognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11282-11286.
92. Van Der Warrenburg B.P., Lammens M., Lucking C.B., Denefle P., Wesseling P., Boolj J., Praamstra P., Quinn N., Brice A. and Horstink M.W. (2001). Clinical and pathologic abnormalities in a family with parkinsonism and parking gene mutations. Neurology 56, 555-557.
93. Vila M., Vukosavich S., Jackson-Lewisky Neysat M., Jakowee M. and Przedborski S. (2000). Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74, 721-729.
94. Wakabayashi K., Hayashi S., Kakita A., Yamada M., Toyoshima Y., Yoshimoto M. and Takahashi H. (1998). Accumulation of α-synucleinNACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96, 445-452
95. Wakabayashi K., Yoshimoto M., Fukushima T., Koide R., Horikawa Y., Morita T. and Takahashi H. (1999). Widespread occurrence of α-synucleinNACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol. Appl. Neurobiol. 25, 363-368.
96. Wang L.Y. and Kaczmarek L.K. (1998). High-frequency firing helps replenish the readily releasable pool of synaptic vesicles. Nature 394, 384-388.
97. Wang M., Suzuki T., Kitada T., Asakawa S., Minoshima S., Shimizu N., Tanaka K., Mizuno Y. and Hattori N. (2001). Developmental changes in the expression of parking and UbcR7, a parking-interacting and ubiquitination conjugating enzyme, in rat brain. J. Neurochem. 77, 1561-1568.
98. Weinreb P.H., Zhen W., Poon A.W., Conway K.A. and Lansbury P.T. Jr. (1996). NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
99. White C.R., Patel R.P. and Darley-Usmar V. (1999). Nitric oxide donor generation from reaction of peroxynitrite. Methods Enzymol. 301, 288-298.
100. Wightman R.M. and Zimmerman J.B. (1990). Control of dopamine extracellular concentration in rat striatum by impulse flow and uptake. Brain Res. Rev. 15, 135-144.
101. Wise R.A. (1996). Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19, 319-340.
102. Withers G.S., George J.M., Banker G.A. and Clayton D.F. (1997). Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87-94.